Kane Biotech (CVE:KNE) Reaches New 1-Year Low – What’s Next?

Kane Biotech Inc. (CVE:KNEGet Free Report) reached a new 52-week low on Monday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 5014 shares. The stock had previously closed at C$0.03.

Kane Biotech Price Performance

The stock has a market cap of C$4.99 million, a PE ratio of -0.33 and a beta of 0.03. The business has a 50-day moving average price of C$0.04 and a 200-day moving average price of C$0.05. The company has a current ratio of 0.80, a quick ratio of 0.39 and a debt-to-equity ratio of -331.42.

About Kane Biotech

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

Further Reading

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.